Novo Nordisk is trading 3.96% up now at €40.71 after a sharp multi-session decline.
- No new company-specific announcement or analyst action dated August 10, 2026 was identified.
- Recent coverage says investors remain concerned about slightly weaker Wegovy pill sales, CagriSema setbacks, U.S. pricing pressure, and pipeline strength despite the raised 2026 outlook.
- The broader market backdrop was mixed and does not clearly explain the move.